Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or

Improvements in technique, as well as advances in technology, have resulted in significant survival advances for those with localized and oligometastatic prostate cancer.

This paper explains the controversy about including all of a large reconstruction flap in the RT target volume versus only the perimeter of the flap. Available guidelines regarding the issue are reviewed as are outcome studies that inform the subject.

This activity provides practitioners with the knowledge of the treatment of lung mass without tissue diagnosis.